Related Experiment Videos
[Viral liver diseases. Current status of therapy] ]
1Ustav chemických léciv Farmaceutické fakulty Veterinární a farmaceutické univerzity, Brno. benes@vfu.cz
Insights
Viral hepatitis, including Hepatitis B (HBV) and Hepatitis C (HCV), affects millions globally. While HBV has a vaccine, HCV remains a challenge due to rapid mutation, but new treatments like NS3 protease inhibitors are emerging.
Area of Science:
- Hepatology and Virology
- Infectious Diseases Epidemiology
Context:
- Viral hepatitis, specifically Hepatitis B (HBV) and Hepatitis C (HCV), represents a significant global health burden with hundreds of millions infected.
- Transmission of HBV and HCV often occurs through non-personal contact routes such as blood transfusions and surgical procedures.
Purpose:
- To highlight the current status of viral hepatitis, focusing on the challenges in treating Hepatitis C (HCV) and the ongoing research for effective therapies and vaccines.
- To underscore the increasing prevalence of HCV, linked to rising rates of drug addiction and HIV co-infection.
Summary:
- Hepatitis B (HBV) is manageable with existing treatments and a vaccine, but Hepatitis C (HCV) presents ongoing difficulties due to the virus's high mutation rate and diverse serotypes, hindering vaccine development.
- Advancements in biological sciences are paving the way for new HCV treatments, including NS3 protease inhibitors and other novel medications, alongside vaccine research.
Impact:
- The development of new treatments and potential vaccines for HCV could significantly reduce the global burden of this chronic liver disease.
- Improved understanding of viral mutation mechanisms in HCV is crucial for developing long-term control strategies and effective public health interventions.
Abstract:
Viral liver diseases, particularly hepatitides of type B (HBV) and C (HCV) show an increasing trend, the number of infected people in the world being several hundred million people. With the exception of other forms (HAV, HDV, HEV, and HGV), where infectivity is also high, possible transmission and infection in HBV and HCV are often independent of the affected person (blood transfusion, stomatological operations, surgery, etc.). Treatment of hepatitides not proceeding into a chronic stage is without any problems at the moment. In the case of HBV, besides chemical drugs which are being developed, vaccination is available. Hepatitis C remains to be a problem of world importance. Its growth in recent years runs parallel to an increase in drug addicts and HIV infection. The difficulties in the development of vaccines are related to rapid mutation of the virus and continuous formation of other serotypes. Progress in many biological disciplines is a certain warranty that the so-called NS3 proteases inhibitors and medicaments of other types, including vaccines, will be introduced into practice for HCV treatment.